News and Events

FEATURED

Visit Lucent Diagnostics at AAIC 2025 

Read now

FEATURED

Advancing Early Alzheimer’s Detection with LucentAD® Complete

A multi-analyte blood test designed to provide clinicians with a practical, non-invasive tool for assessing Alzheimer’s risk with high diagnostic accuracy

Read now

FEATURED

Quanterix Launches High Accuracy p-Tau 217 Blood Biomarker Test to Aid Physician Diagnosis of Alzheimer’s Disease

New test elevates the performance standard for blood biomarker tests intended for detecting amyloid pathology in individuals with cognitive impairment

Read now

FEATURED

Quanterix launches blood test to detect early Alzheimer’s disease

Quanterix Corporation announced the launch of LucentAD, a test to assist in the evaluation of patients experiencing cognitive symptoms consistent with signs of early Alzheimer’s disease.

Read now

FEATURED

Quanterix launches prescription blood test for Alzheimer’s disease

The diagnostics company Quanterix hopes to gain new ground following the FDA’s recent full approval of Eisai and Biogen’s Leqembi treatment for Alzheimer’s disease, with the launch of an ultrasensitive blood test and a refreshed storefront for healthcare providers.

Read now

FEATURED

Quanterix launches LucentAD biomarker test for early Alzheimer’s disease

Quanterix (NASDAQ:QTRX) said that it has launched a biomarker blood test called LucentAD to help diagnose patients experiencing symptoms consistent with early Alzheimer’s disease, or AD.

Read now

FEATURED

Quanterix sees a bright future for blood biomarkers

Qalsody, Biogen’s therapy for a specific form of amyotrophic lateral sclerosis, in April became the first neurological drug whose accelerated approval was based on a levels of a surrogate biomarker in patients’ blood. This is great news for Quanterix, maker of the leading blood test for the biomarker in question, neurofilament light chain.

Read now